表紙
市場調査レポート

子宮頸癌の世界市場 2015-2019年

Global Cervical Cancer Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 339611
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
子宮頸癌の世界市場 2015-2019年 Global Cervical Cancer Market 2015-2019
出版日: 2015年09月09日 ページ情報: 英文 70 Pages
概要

世界の子宮頸癌市場は、2014年から2019年にかけて4.87%のCAGRで成長すると予測されています。

当レポートでは、世界の子宮頸癌市場について分析し、市場の概要や構造、市場規模の動向 、地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

第5章 疾病の概要

  • 疾病の理解
  • リスク要因
  • 兆候・症状
  • スクリーニング
  • 診断
  • 病期
  • 治療
  • 疫学

第6章 市場情勢

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第7章 市場区分:用途別

  • 世界の予防ワクチン市場
  • 世界の治療薬市場

第8章 市場区分:治療タイプ別

  • 世界の子宮頸癌治療市場:治療タイプ別
  • 化学療法
  • 標的療法
  • HPVワクチン

第9章 地域区分

第10章 主要ブランド分析

  • ガーダシル、ガーダシル9およびサーバリックスの比較研究

第11章 パイプラインのポートフォリオ

第12章 市場成長促進因子

第13章 促進因子の影響

第14章 市場の課題

第15章 促進要因と課題の影響

第16章 市場の動向

第17章 ベンダー情勢

  • 競争状況
  • 市場分析
  • その他の有力ベンダー

第18章 主要ベンダーの分析

  • GSK
  • F. Hoffmann-La Roche
  • Merck

第19章 付録

第20章 Technavioについて

図表一覧

目次
Product Code: IRTNTR7066

About cervical cancer

Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.

Technavio's analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.

Technavio's report, Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck

Other Prominent Vendors

  • Advaxis Immunotherapies
  • Bionor Pharma
  • Dendreon Corporation
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Profectus Biosciences
  • Virometix
  • Zeria Pharmaceuticals

Key market driver

  • Increase in incidence rate
  • For a full, detailed list, view our report

Key market challenge

  • Adverse effects of drugs and vaccines
  • For a full, detailed list, view our report

Key market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Screening
  • Diagnosis
  • Staging
  • Treatment
  • Epidemiology

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by application

  • Global prophylactic vaccines market
  • Global therapeutic drugs market

PART 08: Market segmentation by type of therapy

  • Global cervical cancer therapeutics market by type of therapy
  • Chemotherapy
  • Targeted therapy
  • HPV vaccines

PART 09: Geographical segmentation

PART 10: Key brand analysis

  • Comparative study between Gardasil, Gardasil 9, and Cervarix

PART 11: Pipeline portfolio

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • GSK
  • F. Hoffmann-La Roche
  • Merck

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Risk factors for cervical cancer
  • Exhibit 02: Screening tests for cervical cancer
  • Exhibit 03: Diagnostic tests for cervical cancer
  • Exhibit 04: FIGO staging for cervical cancer
  • Exhibit 05: Management of cervical cancer
  • Exhibit 06: Chemotherapy for treatment of cervical cancer
  • Exhibit 07: Cervical cancer treatment algorithm
  • Exhibit 08: Countries with highest cervical cancer rates
  • Exhibit 09: Cervical cancer deaths by age group in the US 2008-2012
  • Exhibit 10: Age-specific incidence rates of cervical cancer in the US by race 2008-2012
  • Exhibit 11: Age-specific mortality rates of cervical cancer of women in the US by race 2008-2012
  • Exhibit 12: Mortality rates of cervical cancer of women in the US by race 2008-2012
  • Exhibit 13: Average number of cervical cancer deaths in EU 2010-2012
  • Exhibit 14: Cervical cancer incidence and mortality rates in EU 2007-2011
  • Exhibit 15: Global cervical cancer therapeutics market 2014-2019 ($ billions)
  • Exhibit 16: Global cervical cancer therapeutics market segmentation by application
  • Exhibit 17: Global prophylactic vaccines market 2014-2019 ($ millions)
  • Exhibit 18: Global therapeutic drugs market 2014-2019 ($ millions)
  • Exhibit 19: Segmentation of global cervical cancer therapeutics market 2014
  • Exhibit 20: Global cervical cancer therapeutics market by type of therapy
  • Exhibit 21: Segmentation of global cervical cancer therapeutics market by region 2014
  • Exhibit 22: Global cervical cancer vaccines market: Comparison of major brands
  • Exhibit 23: Gardasil, Gardasil 9, and Cervarix: A comparative study
  • Exhibit 24: Key late-stage HPV vaccines for cervical cancer
  • Exhibit 25: Drivers of global cervical cancer therapeutics market
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Challenges of global cervical cancer therapeutics market
  • Exhibit 28: Impact of drivers and challenges
  • Exhibit 29: Trends of global cervical cancer therapeutics market
  • Exhibit 30: Gardasil: Global revenue and growth rate 2011-2014
  • Exhibit 31: Merck: Key takeaways
  • Exhibit 32: Cervarix: Global revenue and growth rate 2012-2014
  • Exhibit 33: GSK: Key takeaways
  • Exhibit 34: F. Hoffman-La Roche: Key takeaways
Back to Top